Raymond James & Associates Nkarta, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding NKTX
# of Institutions
129Shares Held
66.5MCall Options Held
173KPut Options Held
20K-
Ra Capital Management, L.P. Boston, MA10.8MShares$26.5 Million0.68% of portfolio
-
Commodore Capital LP New York, NY4.66MShares$11.4 Million1.79% of portfolio
-
Black Rock Inc. New York, NY4.06MShares$9.95 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA4.03MShares$9.87 Million0.97% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA3.77MShares$9.23 Million9.87% of portfolio
About Nkarta, Inc.
- Ticker NKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,656,800
- Market Cap $119M
- Description
- Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...